Biosimilar Enoxaparin for the Prevention or Treatment of Thrombosis and Cardiovascular Conditions


( Last Updated : September 10, 2021)
Project Line:
Reference List
Project Sub Line:
Summary of Abstracts
Project Number:
RB1589-000

Details


Question

  1. What is the clinical effectiveness for adult or pediatric patients of switching from reference to biosimilar enoxaparin in the prevention or treatment of thrombosis and cardiovascular conditions?
  2. What is the comparative clinical effectiveness for adult or pediatric patients of biosimilar versus reference enoxaparin for in prevention or treatment of thrombosis and cardiovascular conditions?



Key Message

Three randomized controlled trials and 1 non-randomized study were identified regarding the comparative clinical effectiveness of biosimilar versus reference enoxaparin in the prevention or treatment of thrombosis and cardiovascular conditions for adult or pediatric patients.
No relevant literature was identified regarding the clinical effectiveness of switching from reference to biosimilar enoxaparin in the prevention or treatment of thrombosis and cardiovascular conditions for adult or pediatric patients